• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
173062 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  # w2 ?- o5 R. V5 [! x
" r( O% u, D% d, f

& K0 a: U$ X8 I8 I$ vSub-category:/ k- p, A* u6 E" M# v- o/ w
Molecular Targets
9 w! W  ~2 J7 Y' J
# W1 }; i3 z: a8 f9 H8 q. S) y9 e) s  ~0 a
Category:: L0 ^$ o) c( p3 L- d1 d7 T
Tumor Biology * h+ a4 ?7 D6 H, q9 C# [! f, j

$ e  q! W  v+ A$ X6 o4 [  \9 J
2 C, O  r5 I8 B1 H* E: ]: y9 eMeeting:
& s) b% @7 B  f: s  T, |9 L: P2011 ASCO Annual Meeting 7 J& E7 q! X  Z6 G3 p( O
3 d( T. S) P$ [: J; A% l

3 a" P% C$ q% ]( S- `9 E; W- ZSession Type and Session Title:
" Q  |" E5 _7 V  l6 bPoster Discussion Session, Tumor Biology
" n  e5 |8 f  k* S8 w' R9 ?* e  N: e3 B& O

+ q+ W# y  W- ^/ Q7 u2 e0 I, ~3 OAbstract No:. M, [  e* X7 ^' M: a
10517 8 A9 E. N7 B$ g5 x5 o: h. z: T! n

0 i; R' r* c- s' e
) \) l% ^: W* i6 n& b5 aCitation:
" q! @$ H' u  l' [, ?- [. `J Clin Oncol 29: 2011 (suppl; abstr 10517)
: q/ c! B  m" D$ `4 P4 [- Z
+ x6 a8 M5 H& d& h- W9 d1 z; X; W  S6 M$ A* K' k
Author(s):$ \2 ~$ c5 U: f5 m
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 2 Q7 k5 [. ]8 M; |( E
+ ?- m  N3 |% ~
) S7 ?6 _' c3 S5 W, j0 b
7 n6 i$ X8 ~+ s
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.0 X5 x! Q  \" P# Z: {  c
$ z' [, G$ m0 w+ _& A6 x. B# H7 g8 x
Abstract Disclosures
6 ^% M* E' X! b+ ~1 g# e7 \  O6 D, ?4 b( m6 J) g& M1 P, |
Abstract:
2 Q5 t+ D2 s- h' T" q& h, Y5 Z' s; n4 S1 N$ x( M. V1 s% Z% H

& Z6 x3 \: y6 X3 FBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.: N. _( H* _1 O, z- p: l/ Z

4 h! e2 V% l: M1 c+ r  }" H3 Z
0 G" S9 @4 p3 G+ W, O7 `
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 2 @. Z: ^+ c8 d
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
# W4 N/ J7 B& E& a% Z
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 ) O5 B3 r& z$ {# L( y2 o
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。# Z, C( L. ]# @$ Z- g1 [
ALK一个指标医院要900多 ...

' w. |" s# |. {' ?平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
) {8 N2 f8 y6 J5 q9 Z- w3 h' A5 i9 I) D6 K3 a
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表